Automated signal pattern evaluation of a bladder cancer specific multiprobe-fish assay applying a user-trainable workstation

Microscopy Research and Technique

Volumn 75, Issue 6, 2012, Pages 814-820

  Pajor, Gabor ^a   Alpar, Donat ^a   Kajtar, Bela ^a   Melegh, Bela ^a   Somogyi, Laszlo ^a   Kneif, Maria ^a   Bollmann, Daniel ^b   Pajor, Laszlo ^a   Sule, Norbert ^c  

^a UNIVERSITY OF PÉCS   (Hungary)

^b Department of Pathology   (Germany)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Adoptable workstation; Automated spot counting; Polysomy; Urovysion

Indexed keywords

AUTOMATION; CELL CULTURE; DIAGNOSIS; DISEASES; FLUORESCENCE MICROSCOPY;

ADOPTABLE WORKSTATION; AUTOMATED-SPOT COUNTING; BLADDER CANCERS; DETECTION ACCURACY; MULTIPROBES; PATTERN EVALUATION; POLYSOMY; SIGNAL ENUMERATION; SIGNAL PATTERNS; UROVYSION;

CELL PROLIFERATION;

EID: 84861347528     PISSN: 1059910X     EISSN: 10970029     Source Type: Journal    
DOI: 10.1002/jemt.21131     Document Type: Article

References (24)

1. Alpár D, Hermesz J, Pótó L, László R, Kereskai L, Jáksó P, Pajor G, Pajor L, Kajtár B. 2008. Automated FISH analysis using dual-fusion and break-apart probes on paraffin-embedded tissue sections. Cytometry A 73: 651-657.
2. Blandin AT, Mühlematter D, Bougeon S, Gogniat C, Porter S, Beyer V, Parlier V, Beckmann JS, van Melle G, Jotterand M. 2008. Automated four-color interphase fluorescence in situ hybridization approach for the simultaneous detection of specific aneuploidies of diagnostic and prognostic significance in high hyperdiploid acute lymphoblastic leukemia. Cancer Genet Cytogenet 186: 69-77.
3. Bubendorf L. 2007. Editorial comment on: The value of the UroVysion® assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol 54: 407.
4. Budman LI, Kassouf W, Steinberg JR. 2008. Biomarkers for detection and surveillance of bladder cancer. Can Urol Assoc J 2: 212.
5. Carrell DT. 2008. The clinical implementation of sperm chromosome aneuploidy testing: Pitfalls and promises. J Androl 29: 124-133.
6. Daniely M, Rona R, Kaplan T, Olsfanger S, Elboim L, Zilberstien Y, Friberger A, Kidron D, Kaplan E, Lew S, Leibovitch I. 2005. Combined analysis of morphology and fluorescence in situ hybridization significantly increases accuracy of bladder cancer detection in voided urine samples. Urology 66: 1354.
7. Erlecke J, Hartmann I, Hoffmann M, Kroll T, Starke H, Heller A, Gloria A, Sayer HG, Johannes T, Claussen U, Liehr T, Loncarevic IF. 2009. Automated detection of residual cells after sex-mismatched stem-cell transplantation - evidence for presence of disease-marker negative residual cells. Mol Cytogenet 29: 12.
8. Johnson KL, Stroh H, Khosrotehrani K, Bianchi DW. 2007. Spot counting to locate fetal cells in maternal blood and tissue: a comparison of manual and automated microscopy. Microsc Res Tech 70: 585-588.
9. Kajtár B, Méhes G, Lörch T, Deák L, Kneifné M, Alpár D, Pajor L. 2006. Automated fluorescent in situ hybridization (FISH) analysis of t(9;22)(q34;q11) in interphase nuclei. Cytometry A 69: 506-514.
10. Kipp BR, Tanasescu M, Else TA, Bryant SC, Karnes RJ, Sebo TJ, Halling KC. 2009. Quantitative fluorescence in situ hybridization and its ability to predict bladder cancer recurrence and progression to muscle-invasive bladder cancer. J Mol Diagn 11: 148.
11. Kozubek M, Kozubek S, Lukásová E, Marecková A, Bártová E, Skalníková M, Jergová A. 1999. High-resolution cytometry of FISH dots in interphase cell nuclei. Cytometry 36: 279-293.
12. Liou LS. 2006. Urothelial cancer biomarkers for detection and surveillance. Urology 67: 25.
13. Lokeshwar VB, Habuchi T, Grossman HB, Murphy WM, Hautmann SH, Hemstreet GP3rd, Bono AV, Getzenberg RH, Goebell P, Schmitz-Dräger BJ, Schalken JA, Fradet Y, Marberger M, Messing E, Droller MJ. 2005. Bladder tumor markers beyond cytology: International Consensus Panel on bladder tumor markers. Urology 66: 35.
14. Marganski WA, El-Sirgany Costa V, Kilpatrick MW, Tafas T, Yim J, Hatthews M. 2011. Digitized microscopy in the diagnosis of bladder cancer: analysis of >3000 cases during a 7-month period. Cancer Cytopath 119: 279-289.
15. Martín-Subero JI, Chudoba I, Harder L, Gesk S, Grote W, Novo FJ, Calasanz MJ, Siebert R. 2002. Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol 161: 413-420.
16. Moore DH, II, Epstein L, Reeder J, Wheeless L, Waldman FM. 1996. Interlaboratory variability in fluorescence in situ hybridization analysis. The NCI Bladder Tumor Marker Network. Cytometry 25: 125.
17. Netten H, Young IT, van Vliet LJ, Tanke HJ, Vroljik H, Sloos WC. 1997. FISH and chips: Automation of fluorescent dot counting in interphase cell nuclei. Cytometry 28: 1-10.
18. Pajor G, Somogyi L, Melegh B, Alpar D, Kajtar B, Farkas L, Kneif M, Bollmann D, Pajor L, Sule N. 2011. Urovysion: Considerations on modifying current evaluation scheme, including immunophenotypic targeting and locally set statistically derived diagnostic criteria. Cytometry A 79: 375-382.
19. Pajor G, Sule N, Alpar D, Kajtar B, Kneif M, Bollmann D, Somogyi L, Pajor L. 2008. Increased efficiency of detecting genetically aberrant cells by UroVysion test on voided urine specimens using automated immunophenotypical preselection of uroepithelial cells. Cytometry A 73: 259.
20. Pycha A. 2007. FISH: A tool we really need? Eur Urol 52: 630.
21. Riesz P, Lotz G, Páska C, Szendrôi A, Majoros A, Németh Z, Törzsök P, Szarvas T, Kovalszky I, Schaff Z, Romics I, Kiss A. 2007. Detection of bladder cancer from the urine using fluorescence in situ hybridization technique. Pathol Oncol Res 13: 18.
22. Smith GD, Bentz JS. 2010. "FISHing" to detect urinary and other cancers: Validation of an imaging system to aid in interpretation. Cancer Cytopathol 118: 56-64.
23. Sokolova IA, Halling KC, Jenkins RB, Burkhardt HM, Meyer RG, Seelig SA, King W. 2000. The Development of a multitarget, multicolor fluorescence in situ hybridization assay for the detection of urothelial carcinoma in urine. J Mol Diagn 2: 116.
24. Vrooman OPJ, Witjes AJ. 2008. Urinary markers in bladder cancer. Eur Urol 53: 909.